What’s up with all the buzz about Gilead’s PhIII NASH drug selonsertib?

Earlier today we could detect a distinct change in the biotech force as some careful students of clinicaltrials.gov picked up on some major — and recently filed — changes in the timelines listed for a readout on Gilead’s $GILD closely-watched NASH drug selonsertib.